11 May 2016 - Bristol-Myers Squibb Company announced today that the EC has approved Opdivo in combination with Yervoy for the treatment of advanced (unresectable or metastatic) melanoma in adults, representing the first and only approved combination of two immuno-oncology agents in the EU.

This approval allows for the marketing of the Opdivo + Yervoy Regimen in all 28 Member States of the EU. Approval was based on CheckMate -067, the first Phase 3, double-blind, randomized study, in which the Opdivo + Yervoy Regimen and Opdivo monotherapy demonstrated superior progression-free survival (PFS) and objective response rates (ORR) in patients with advanced melanoma, regardless of BRAF mutational status, versus Yervoy alone. The safety profile was consistent with previously reported studies evaluating the Opdivo + Yervoy Regimen, and most treatment-related adverse events were managed using established algorithms.

For more details, go to: http://news.bms.com/press-release/cancer/european-commission-approves-first-and-only-immuno-oncology-combination-bristol